If future studies on dosage and short- and long-term outcomes of AA and DHA supplementation agree with the results, about 50% of infants with ROP who need treatment might be avoided.13 Thus, many premature infants may be spared 1 or repeated laser treatment sessions with general anesthesia or intravitreal injections of anti–vascular endothelial growth factor drugs. The gene discussed is VEGFA; the disease is retinopathy of prematurity.